Medical Devices; Physical Medicine Devices; Classification of the Nonpowered Lower Extremity Pressure Wrap, 37948-37950 [2014-15626]
Download as PDF
37948
Federal Register / Vol. 79, No. 128 / Thursday, July 3, 2014 / Rules and Regulations
Æ a summary of the expected risks
and benefits of using the device;
Æ a summary of the clinical
performance data, including
information on the patient population
for which the device has and has not
been demonstrated to be effective, and
any adverse events and complications;
Æ information on how the device
operates and the typical sensations
experienced during treatment;
Æ a detailed summary of the device
technical parameters;
Æ an expiration date/shelf life for the
electrodes and the number of times they
can be reused; and
Æ disposal instructions.
Section 510(m) of the FD&C Act
provides that FDA may exempt a class
II device from the premarket notification
requirements under section 510(k) of the
FD&C Act if FDA determines that
premarket notification is not necessary
to provide reasonable assurance of the
safety and effectiveness of the device.
For this type of device, FDA has
determined that premarket notification
is necessary to provide reasonable
assurance of the safety and effectiveness
of the device. Therefore, this device
type is not exempt from premarket
notification requirements. Persons who
intend to market this type of device
must submit to FDA a premarket
notification prior to marketing the
device, which contains information
about the transcutaneous electrical
nerve stimulator to treat headache
device they intend to market.
II. Environmental Impact
The Agency has determined under 21
CFR 25.34(b) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
ehiers on DSK2VPTVN1PROD with RULES
III. Paperwork Reduction Act of 1995
This final administrative order
establishes special controls that refer to
previously approved collections of
information found in other FDA
regulations. These collections of
information are subject to review by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3520). The
collections of information in part 807,
subpart E, regarding premarket
notification submissions have been
approved under OMB control number
0910–0120, and the collections of
information in 21 CFR part 801,
regarding labeling, have been approved
under OMB control number 0910–0485.
VerDate Mar<15>2010
13:50 Jul 02, 2014
Jkt 232001
IV. Reference
The following reference has been
placed on display in the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852,
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday, and is available
electronically at https://
www.regulations.gov.
1. K122566 De Novo Petition for the Cefaly
Device From STX–Med SPRL, dated
December 13, 2012.
List of Subjects in 21 CFR Part 882
Medical devices, Neurological
devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 882 is
amended as follows:
PART 882—NEUROLOGICAL DEVICES
1. The authority citation for 21 CFR
part 882 continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 371.
2. Add § 882.5891 to subpart F to read
as follows:
■
§ 882.5891 Transcutaneous electrical
nerve stimulator to treat headache.
(a) Identification. A transcutaneous
electrical nerve stimulator to treat
headache is a device used to apply an
electrical current to a patient’s cranium
through electrodes placed on the skin.
(b) Classification. Class II (special
controls). The special controls for this
device are:
(1) The patient-contacting
components of the device must be
demonstrated to be biocompatible.
(2) Appropriate analysis/testing must
validate electromagnetic compatibility
and electrical, mechanical, and thermal
safety.
(3) The technical parameters of the
device, including waveform, output
modes, maximum output voltage and
current (with 500, 2,000, and 10,000
ohm loads), pulse duration, frequency,
net charge (mC) per pulse, maximum
phase charge at 500 ohms, maximum
current density (mA/cm2, r.m.s.),
maximum average current (mA),
maximum average power density (W/
cm2), and the type of impedance
monitoring system must be fully
characterized.
(4) Electrical performance, adhesive
integrity, shelf life, reusability, and
current distribution testing of the
electrodes must be conducted.
PO 00000
Frm 00022
Fmt 4700
Sfmt 4700
(5) Appropriate software verification,
validation, and hazard analysis must be
performed.
(6) Clinical performance data must
demonstrate that the device is safe and
effective as a treatment for headache in
the indicated patient population.
(7) Labeling must include the
following:
(i) Appropriate contraindications such
as not for use in subjects with an
implanted metallic or electronic device
in the head, a cardiac pacemaker, or an
implanted or wearable defibrillator.
(ii) Appropriate warnings such as not
to apply the device on the neck or chest,
not to use the device in the presence of
electronic monitoring equipment, not to
use in the bath or shower, not to use
while sleeping, not to use while driving,
not to use while operating machinery.
(iii) Appropriate precautions such as
the long-term effects of chronic use of
the device are unknown.
(iv) A summary of the expected risks
and benefits of using the device.
(v) A summary of the clinical
performance data, including
information on the patient population
for which the device has and has not
been demonstrated to be effective, and
any adverse events and complications.
(vi) Information on how the device
operates and the typical sensations
experienced during treatment.
(vii) A detailed summary of the device
technical parameters.
(viii) An expiration date/shelf life for
the electrodes and the number of times
they can be reused.
(ix) Disposal instructions.
Dated: June 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–15625 Filed 7–2–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 890
[Docket No. FDA–2014–M–0701]
Medical Devices; Physical Medicine
Devices; Classification of the
Nonpowered Lower Extremity Pressure
Wrap
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final order.
The Food and Drug
Administration (FDA) is classifying the
nonpowered lower extremity pressure
SUMMARY:
E:\FR\FM\03JYR1.SGM
03JYR1
Federal Register / Vol. 79, No. 128 / Thursday, July 3, 2014 / Rules and Regulations
ehiers on DSK2VPTVN1PROD with RULES
wrap into class I (general controls). The
Agency is classifying the device into
class I (general controls) in order to
provide a reasonable assurance of safety
and effectiveness of the device.
DATES: This order is effective August 4,
2014. The classification was applicable
on December 18, 2013.
FOR FURTHER INFORMATION CONTACT:
Michael Hoffmann, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1434, Silver Spring,
MD 20993–0002, 301–796–6476,
michael.hoffmann@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In accordance with section 513(f)(1) of
the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C.
360c(f)(1)), devices that were not in
commercial distribution before May 28,
1976 (the date of enactment of the
Medical Device Amendments of 1976),
generally referred to as postamendments
devices, are classified automatically by
statute into class III without any FDA
rulemaking process. These devices
remain in class III and require
premarket approval, unless and until
the device is classified or reclassified
into class I or II, or FDA issues an order
finding the device to be substantially
equivalent, in accordance with section
513(i) of the FD&C Act, to a predicate
device that does not require premarket
approval. The Agency determines
whether new devices are substantially
equivalent to predicate devices by
means of premarket notification
procedures in section 510(k) of the
FD&C Act (21 U.S.C. 360(k)) and 21 CFR
part 807 of the regulations.
Section 513(f)(2) of the FD&C Act, as
amended by section 607 of the Food and
Drug Administration Safety and
Innovation Act (Pub. L. 112–144),
provides two procedures by which a
person may request FDA to classify a
device under the criteria set forth in
section 513(a)(1). Under the first
procedure, the person submits a
premarket notification under section
510(k) of the FD&C Act for a device that
has not previously been classified and,
within 30 days of receiving an order
classifying the device into class III
under section 513(f)(1) of the FD&C Act,
the person requests a classification
under section 513(f)(2). Under the
second procedure, rather than first
submitting a premarket notification
under section 510(k) and then a request
for classification under the first
procedure, the person determines that
there is no legally marketed device upon
which to base a determination of
VerDate Mar<15>2010
13:50 Jul 02, 2014
Jkt 232001
substantial equivalence and requests a
classification under section 513(f)(2) of
the FD&C Act. If the person submits a
request to classify the device under this
second procedure, FDA may decline to
undertake the classification request if
FDA identifies a legally marketed device
that could provide a reasonable basis for
review of substantial equivalence with
the device or if FDA determines that the
device submitted is not of ‘‘lowmoderate risk’’ or that general controls
would be inadequate to control the risks
and special controls to mitigate the risks
cannot be developed.
In response to a request to classify a
device under either procedure provided
by section 513(f)(2) of the FD&C Act,
FDA will classify the device by written
order within 120 days. This
classification will be the initial
classification of the device. In
accordance with section 513(f)(1) of the
FD&C Act, FDA issued an order on
January 7, 2011, classifying the Restless
Legs Device, into class III, because it
was not substantially equivalent to a
device that was introduced or delivered
for introduction into interstate
commerce for commercial distribution
before May 28, 1976, or a device which
was subsequently reclassified into class
I or class II. On January 23, 2011, Mary
M. Sorg dba PJ Sleeper’s, submitted a
request for classification of the Restless
Leg Device under section 513(f)(2) of the
FD&C Act. The manufacturer
recommended that the device be
classified into class I (Ref. 1).
In accordance with section 513(f)(2) of
the FD&C Act, FDA reviewed the
request in order to classify the device
under the criteria for classification set
forth in section 513(a)(1) of the FD&C
Act. FDA classifies devices into class I
if general controls by themselves are
sufficient to provide reasonable
assurance of safety and effectiveness of
the device for its intended use. After
review of the information submitted in
the de novo request, FDA determined
that the device can be classified into
class I. FDA believes general controls
will provide reasonable assurance of the
safety and effectiveness of the device.
Therefore, on December 18, 2013,
FDA issued an order to the requester
classifying the device into class I. FDA
is codifying the classification of the
device by adding § 890.5760. The device
is assigned the generic name
nonpowered lower extremity pressure
wrap, and it is identified as a
prescription device that applies
mechanical pressure by wrapping
around the lower extremity, such as the
leg or foot, and is intended for primary
Restless Leg Syndrome.
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
37949
FDA believes that general controls
provide reasonable assurance of safety
and effectiveness. Nonpowered lower
extremity pressure wraps are
prescription devices restricted to patient
use only upon the authorization of a
practitioner licensed by law to
administer or use the device. ((21 CFR
882.1440(a)); see section 520(e) of the
FD&C Act (21 U.S.C. 360j(e)) and 21
CFR 801.109 (Prescription devices).)
Prescription-use restrictions are a type
of general controls as defined in section
513(a)(1)(A)(i) of the FD&C Act.
II. Environmental Impact
The Agency has determined under 21
CFR 25.34(b) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
III. Paperwork Reduction Act of 1995
This final administrative order
establishes special controls that refer to
previously approved collections of
information found in other FDA
regulations. These collections of
information are subject to review by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3520). The
collections of information in 21 CFR
part 801, regarding labeling, have been
approved under OMB control number
0910–0485.
IV. Reference
The following reference has been
placed on display in the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852,
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday, and is available
electronically at https://
www.regulations.gov.
1. Request for automatic Class III
designation under (De Novo) 513(f)(2)
510(k)# K102707, from Mary M. Sorg dba PJ
Sleeper’s, January 23, 2011.
List of Subjects in 21 CFR Part 890
Medical devices, Physical medicine
devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 890 is
amended as follows:
E:\FR\FM\03JYR1.SGM
03JYR1
37950
Federal Register / Vol. 79, No. 128 / Thursday, July 3, 2014 / Rules and Regulations
1. The authority citation for 21 CFR
part 890 continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 371.
2. Add § 890.5760 to subpart F to read
as follows:
■
§ 890.5760 Nonpowered lower extremity
pressure wrap.
(a) Identification. A nonpowered
lower extremity pressure wrap is a
prescription device that applies
mechanical pressure by wrapping
around the lower extremity, such as the
leg or foot, and is intended for primary
Restless Leg Syndrome.
(b) Classification. Class I (general
controls). The device is exempt from the
premarket notification procedures in
subpart E of part 807 of this chapter,
subject to the limitations in § 890.9.
Dated: June 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–15626 Filed 7–2–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
33 CFR Part 100
[Docket No. USCG–2014–0360]
Special Local Regulation; Eleventh
Coast Guard District Annual Marine
Events
Coast Guard, DHS.
Notice of Enforcement of
Regulation.
AGENCY:
ACTION:
The Coast Guard will enforce
the San Diego Maritime Museum Tall
Ship Festival of Sail special local
regulations during this year’s event on
August 29, 2014 through September 1,
2014. This event occurs on the
navigable waters of the San Diego Bay
in San Diego, CA. These special local
regulations are necessary to provide for
the safety of the participants, crew,
spectators, sponsor vessels of the boat
parade, and general users of the
waterway. During the enforcement
period, persons and vessels are
prohibited from entering into, transiting
through, or anchoring within this
regulated area unless authorized by the
Captain of the Port, or his designated
representative.
ehiers on DSK2VPTVN1PROD with RULES
SUMMARY:
VerDate Mar<15>2010
13:50 Jul 02, 2014
Jkt 232001
This rule is effective from 9 a.m.
to 7 p.m. on August 29, 2014 through
September 1, 2014.
DATES:
PART 890—PHYSICAL MEDICINE
DEVICES
If
you have questions on this notice, call
or email Petty Officer Giacomo Terrizzi,
Waterways Management, U.S. Coast
Guard Sector San Diego, CA; telephone
(619) 278–7656, email D11-PFMarineEventsSanDiego@uscg.mil.
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
The Coast Guard will enforce the
special local regulations in 33 CFR
100.1101 in support of San Diego
Maritime Museum Tall Ship Festival of
Sail (Item 15 on Table 1 of 33 CFR
100.1101), held on a weekend in
September. The Coast Guard will
enforce the special local regulations on
the San Diego Bay in San Diego, CA on
Friday August 29, 2014 through Monday
September 1, 2014 from 9 a.m. to 7 p.m.
Under the provisions of 33 CFR
100.1101, persons and vessels are
prohibited from entering into, transiting
through or anchoring within this
regulated area unless authorized by the
Captain of the Port, or his designated
representative. The Coast Guard may be
assisted by other Federal, State, or local
law enforcement agencies in the patrol
and notification of the regulation.
This document is issued under
authority of 5 U.S.C. 552(a) and 33 CFR
100.1101. In addition to this document
in the Federal Register, the Coast Guard
will provide the maritime community
with advance notification of this
enforcement period via the Local Notice
to Mariners and local advertising by the
event sponsor.
If the Captain of the Port Sector San
Diego or his designated representative
determines that the regulated area need
not be enforced for the full duration
stated on this notice, he or she may use
a Broadcast Notice to Mariners or other
communications coordinated with the
event sponsor to grant general
permission to enter the regulated area.
Dated: June 5, 2014.
J.A. Janszen,
Commander, U.S. Coast Guard, Acting
Captain of the Port San Diego.
[FR Doc. 2014–15543 Filed 7–2–14; 8:45 am]
BILLING CODE 9110–04–P
PO 00000
Frm 00024
Fmt 4700
Sfmt 4700
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
33 CFR Part 165
[Docket Number USCG–2014–0160]
RIN 1625–AA00
Safety Zone; Swim Around Charleston,
Charleston, SC
Coast Guard, DHS.
Temporary final rule.
AGENCY:
ACTION:
The Coast Guard is
establishing a temporary moving safety
zone during the Swim Around
Charleston, a swimming race occurring
on waters of the Wando River, the
Cooper River, Charleston Harbor, and
the Ashley River, in Charleston, South
Carolina. The Swim Around Charleston
is scheduled to take place on September
21, 2014. The temporary safety zone is
necessary for the safety of the
swimmers, participant vessels,
spectators, and the general public
during the event. Persons and vessels
are prohibited from entering, transiting
through, anchoring in, or remaining
within the safety zone unless authorized
by the Captain of the Port Charleston or
a designated representative.
DATES: This rule will be effective from
11:30 a.m. until 6:30 p.m. on September
21, 2014.
ADDRESSES: Documents mentioned in
this preamble are part of docket USCG–
2014–0160. To view documents
mentioned in this preamble as being
available in the docket, go to https://
www.regulations.gov, type the docket
number in the ‘‘SEARCH’’ box and click
‘‘SEARCH.’’ Click on Open Docket
Folder on the line associated with this
rulemaking. You may also visit the
Docket Management Facility in Room
W12–140 on the ground floor of the
Department of Transportation West
Building, 1200 New Jersey Avenue SE.,
Washington, DC 20590, between 9 a.m.
and 5 p.m., Monday through Friday,
except Federal holidays.
FOR FURTHER INFORMATION CONTACT: If
you have questions on this rule, call or
email Chief Warrant Officer Christopher
Ruleman, Sector Charleston Waterways
Management, U.S. Coast Guard;
telephone (843) 740–3184, email
christopher.l.ruleman@uscg.mil. If you
have questions on viewing the docket,
call Cheryl Collins, Program Manager,
Docket Operations, telephone 202–366–
9826.
SUPPLEMENTARY INFORMATION:
SUMMARY:
E:\FR\FM\03JYR1.SGM
03JYR1
Agencies
[Federal Register Volume 79, Number 128 (Thursday, July 3, 2014)]
[Rules and Regulations]
[Pages 37948-37950]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-15626]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 890
[Docket No. FDA-2014-M-0701]
Medical Devices; Physical Medicine Devices; Classification of the
Nonpowered Lower Extremity Pressure Wrap
AGENCY: Food and Drug Administration, HHS.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is classifying the
nonpowered lower extremity pressure
[[Page 37949]]
wrap into class I (general controls). The Agency is classifying the
device into class I (general controls) in order to provide a reasonable
assurance of safety and effectiveness of the device.
DATES: This order is effective August 4, 2014. The classification was
applicable on December 18, 2013.
FOR FURTHER INFORMATION CONTACT: Michael Hoffmann, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 1434, Silver Spring, MD 20993-0002, 301-
796-6476, michael.hoffmann@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In accordance with section 513(f)(1) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 360c(f)(1)), devices that were
not in commercial distribution before May 28, 1976 (the date of
enactment of the Medical Device Amendments of 1976), generally referred
to as postamendments devices, are classified automatically by statute
into class III without any FDA rulemaking process. These devices remain
in class III and require premarket approval, unless and until the
device is classified or reclassified into class I or II, or FDA issues
an order finding the device to be substantially equivalent, in
accordance with section 513(i) of the FD&C Act, to a predicate device
that does not require premarket approval. The Agency determines whether
new devices are substantially equivalent to predicate devices by means
of premarket notification procedures in section 510(k) of the FD&C Act
(21 U.S.C. 360(k)) and 21 CFR part 807 of the regulations.
Section 513(f)(2) of the FD&C Act, as amended by section 607 of the
Food and Drug Administration Safety and Innovation Act (Pub. L. 112-
144), provides two procedures by which a person may request FDA to
classify a device under the criteria set forth in section 513(a)(1).
Under the first procedure, the person submits a premarket notification
under section 510(k) of the FD&C Act for a device that has not
previously been classified and, within 30 days of receiving an order
classifying the device into class III under section 513(f)(1) of the
FD&C Act, the person requests a classification under section 513(f)(2).
Under the second procedure, rather than first submitting a premarket
notification under section 510(k) and then a request for classification
under the first procedure, the person determines that there is no
legally marketed device upon which to base a determination of
substantial equivalence and requests a classification under section
513(f)(2) of the FD&C Act. If the person submits a request to classify
the device under this second procedure, FDA may decline to undertake
the classification request if FDA identifies a legally marketed device
that could provide a reasonable basis for review of substantial
equivalence with the device or if FDA determines that the device
submitted is not of ``low-moderate risk'' or that general controls
would be inadequate to control the risks and special controls to
mitigate the risks cannot be developed.
In response to a request to classify a device under either
procedure provided by section 513(f)(2) of the FD&C Act, FDA will
classify the device by written order within 120 days. This
classification will be the initial classification of the device. In
accordance with section 513(f)(1) of the FD&C Act, FDA issued an order
on January 7, 2011, classifying the Restless Legs Device, into class
III, because it was not substantially equivalent to a device that was
introduced or delivered for introduction into interstate commerce for
commercial distribution before May 28, 1976, or a device which was
subsequently reclassified into class I or class II. On January 23,
2011, Mary M. Sorg dba PJ Sleeper's, submitted a request for
classification of the Restless Leg Device under section 513(f)(2) of
the FD&C Act. The manufacturer recommended that the device be
classified into class I (Ref. 1).
In accordance with section 513(f)(2) of the FD&C Act, FDA reviewed
the request in order to classify the device under the criteria for
classification set forth in section 513(a)(1) of the FD&C Act. FDA
classifies devices into class I if general controls by themselves are
sufficient to provide reasonable assurance of safety and effectiveness
of the device for its intended use. After review of the information
submitted in the de novo request, FDA determined that the device can be
classified into class I. FDA believes general controls will provide
reasonable assurance of the safety and effectiveness of the device.
Therefore, on December 18, 2013, FDA issued an order to the
requester classifying the device into class I. FDA is codifying the
classification of the device by adding Sec. 890.5760. The device is
assigned the generic name nonpowered lower extremity pressure wrap, and
it is identified as a prescription device that applies mechanical
pressure by wrapping around the lower extremity, such as the leg or
foot, and is intended for primary Restless Leg Syndrome.
FDA believes that general controls provide reasonable assurance of
safety and effectiveness. Nonpowered lower extremity pressure wraps are
prescription devices restricted to patient use only upon the
authorization of a practitioner licensed by law to administer or use
the device. ((21 CFR 882.1440(a)); see section 520(e) of the FD&C Act
(21 U.S.C. 360j(e)) and 21 CFR 801.109 (Prescription devices).)
Prescription-use restrictions are a type of general controls as defined
in section 513(a)(1)(A)(i) of the FD&C Act.
II. Environmental Impact
The Agency has determined under 21 CFR 25.34(b) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
III. Paperwork Reduction Act of 1995
This final administrative order establishes special controls that
refer to previously approved collections of information found in other
FDA regulations. These collections of information are subject to review
by the Office of Management and Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of
information in 21 CFR part 801, regarding labeling, have been approved
under OMB control number 0910-0485.
IV. Reference
The following reference has been placed on display in the Division
of Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD 20852, and may be seen by
interested persons between 9 a.m. and 4 p.m., Monday through Friday,
and is available electronically at https://www.regulations.gov.
1. Request for automatic Class III designation under (De Novo)
513(f)(2) 510(k) K102707, from Mary M. Sorg dba PJ
Sleeper's, January 23, 2011.
List of Subjects in 21 CFR Part 890
Medical devices, Physical medicine devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
890 is amended as follows:
[[Page 37950]]
PART 890--PHYSICAL MEDICINE DEVICES
0
1. The authority citation for 21 CFR part 890 continues to read as
follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.
0
2. Add Sec. 890.5760 to subpart F to read as follows:
Sec. 890.5760 Nonpowered lower extremity pressure wrap.
(a) Identification. A nonpowered lower extremity pressure wrap is a
prescription device that applies mechanical pressure by wrapping around
the lower extremity, such as the leg or foot, and is intended for
primary Restless Leg Syndrome.
(b) Classification. Class I (general controls). The device is
exempt from the premarket notification procedures in subpart E of part
807 of this chapter, subject to the limitations in Sec. 890.9.
Dated: June 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-15626 Filed 7-2-14; 8:45 am]
BILLING CODE 4164-01-P